Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Antimicrob Agents Chemother ; 60(3): 1343-8, 2015 Dec 14.
Artículo en Inglés | MEDLINE | ID: mdl-26666939

RESUMEN

A high fosfomycin resistance rate was observed in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) in our previous study, but little is known about its mechanisms. In this study, we explored the prevalence of plasmid-mediated fosfomycin resistance determinants among fosfomycin-resistant KPC-KP strains from a Chinese university hospital and determined the complete sequence of a novel fosA3-carrying plasmid isolated from an epidemic K. pneumoniae sequence type (ST) 11 strain. A total of 97 KPC-KP strains were studied, of which 57 (58.8%) were resistant to fosfomycin, including 44 (45.4%) harboring fosA3 and 1 harboring fosA. All fosA3-positive strains belonged to the dominant ST11-pulse type (PT) A clone according to multilocus sequence typing and pulsed-field gel electrophoresis, suggesting clonal dissemination. The fosA-positive isolate belonged to ST11-PTE. The fosA3-carrying plasmid pKP1034 is 136,848 bp in length and is not self-transmissible. It is a multireplicon plasmid belonging to IncR-F33:A-: B-. Besides fosA3, a variety of other resistance determinants, including blaKPC-2, rmtB, blaCTX-M-65, and blaSHV-12, are identified in pKP1034, which would allow for coselection of fosA3 by most ß-lactams and/or aminoglycosides and facilitate its dissemination despite limited use of fosfomycin in China. Detailed comparisons with related plasmids revealed that pKP1034 is highly mosaic and might have evolved from alarming recombination of the blaKPC-2-carrying plasmid pKPC-LK30 from Taiwan and the epidemic fosA3-carrying plasmid pHN7A8 from mainland China.


Asunto(s)
Proteínas Bacterianas/genética , Farmacorresistencia Bacteriana/genética , Klebsiella pneumoniae/genética , Plásmidos/genética , Secuencia de Bases , China/epidemiología , Farmacorresistencia Bacteriana/efectos de los fármacos , Electroforesis en Gel de Campo Pulsado , Epidemias , Fosfomicina/farmacología , Humanos , Infecciones por Klebsiella/epidemiología , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Tipificación de Secuencias Multilocus , beta-Lactamasas/genética , beta-Lactamasas/metabolismo
2.
Virol J ; 12: 87, 2015 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-26063382

RESUMEN

BACKGROUND: Several studies have suggested a relationship between hepatitis B virus (HBV) basal core promoter/pre-core mutations and HBV-induced acute-on-chronic liver failure (ACLF). Therefore, we evaluated this potential relationship using a meta-analysis. METHODS: Chinese or English studies from 1966 to January 31, 2014 were included in the analysis. A random or fixed-effects model was used to merge the odds ratios (ORs). RESULTS: We identified 31 case-control studies containing a total population of 1995 ACLF and 3822 chronic hepatitis B (CHB) patients. Several mutations were significantly correlated with ACLF: T1753V (1.889, 95 % confidence interval (CI) [1.357-2.631]), A1762T (2.696 [2.265-3.207]), G1764A (3.005 [2.077-4.347]), A1762T/G1764A (2.379 [1.519-3.727]), C1766T (1.849 [1.403-2.437]), T1768A (2.440 [1.405-3.494]), A1846T (3.163 [2.157-4.639]), G1896A (2.181 [1.800-2.642]), G1899A (3.569 [2.906-4.385]) and G1896A/A1762T/G1764A (1.575 [1.172-2.116]). Additionally, HBeAg-negative status was also statistically significant for the progression to ACLF (OR = 2.813, 95 % CI = 2.240-3.533, p < 0.001). However, there was no association between ACLF development and HBV genotype. CONCLUSIONS: The HBV basal core promoter/pre-core mutations T1753V, A1762T, G1764A, C1766T, T1768A, A1846T, G1896A and G1899A, and an HBeAg-negative status correlate with an increased risk of HBV-ACLF.


Asunto(s)
Insuficiencia Hepática Crónica Agudizada/epidemiología , Insuficiencia Hepática Crónica Agudizada/virología , Antígenos e de la Hepatitis B/genética , Virus de la Hepatitis B/genética , Mutación , Regiones Promotoras Genéticas , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Modelos Estadísticos , Medición de Riesgo , Adulto Joven
3.
Antimicrob Agents Chemother ; 58(1): 297-303, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24165187

RESUMEN

Because of its remarkable ability to acquire antibiotic resistance and to survive in nosocomial environments, Acinetobacter baumannii has become a significant nosocomial infectious agent worldwide. Tigecycline is one of the few therapeutic options for treating infections caused by A. baumannii isolates. However, tigecycline resistance has increasingly been reported. Our aim was to assess the prevalence and characteristics of efflux-based tigecycline resistance in clinical isolates of A. baumannii collected from a hospital in China. A total of 74 A. baumannii isolates, including 64 tigecycline-nonsusceptible A. baumannii (TNAB) and 10 tigecycline-susceptible A. baumannii (TSAB) isolates, were analyzed. The majority of them were determined to be positive for adeABC, adeRS, adeIJK, and abeM, while the adeE gene was found in only one TSAB isolate. Compared with the levels in TSAB isolates, the mean expression levels of adeB, adeJ, adeG, and abeM in TNAB isolates were observed to increase 29-, 3-, 0.7-, and 1-fold, respectively. The efflux pump inhibitors (EPIs) phenyl-arginine-ß-naphthylamide (PAßN) and carbonyl cyanide 3-chlorophenylhydrazone (CCCP) could partially reverse the resistance pattern of tigecycline. Moreover, the tetX1 gene was detected in 12 (18.8%) TNAB isolates. To our knowledge, this is the first report of the tetX1 gene being detected in A. baumannii isolates. ST208 and ST191, which both clustered into clonal complex 92 (CC92), were the predominant sequence types (STs). This study showed that the active efflux pump AdeABC appeared to play important roles in the tigecycline resistance of A. baumannii. The dissemination of TNAB isolates in our hospital is attributable mainly to the spread of CC92.


Asunto(s)
Acinetobacter baumannii/efectos de los fármacos , Antibacterianos/farmacología , Minociclina/análogos & derivados , Acinetobacter baumannii/genética , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Hospitales Universitarios , Pruebas de Sensibilidad Microbiana , Minociclina/farmacología , Epidemiología Molecular , Tigeciclina
4.
Neurol Sci ; 35(2): 303-5, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24362852

RESUMEN

Tuberculous meningitis (TBM) is common infectious disease. Early diagnosis and timely treatment are critical for the cure of the disease. Thwaites standard is widely accepted but not the golden standard. Here, we analyzed 42 cases of TBM patients in local hospital and combined with literature review to provide more information in TBM management.


Asunto(s)
Tuberculosis Meníngea/diagnóstico , Tuberculosis Meníngea/terapia , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Tuberculosis Meníngea/patología , Tuberculosis Meníngea/fisiopatología , Adulto Joven
5.
BMC Infect Dis ; 12: 373, 2012 Dec 23.
Artículo en Inglés | MEDLINE | ID: mdl-23259910

RESUMEN

BACKGROUND: Emergence of rmtB-positive Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) poses a great threat to antimicrobial treatment options. METHODS: From January 2010 to December 2010, non-duplicate KPC-KP isolates from our hospital were screened for rmtB and multiple other resistance determinants with PCR. Subsequent studies included MIC determination, PFGE, and multilocus sequence typing. Records from patients with KPC-KP isolated were retrospectively reviewed. Comparisons of molecular and clinical characteristics between rmtB-positive and rmtB-negative isolates were systematically performed, as well as the environmental colonization study in ICU wards. RESULTS: A total of 84 KPC-KP strains were collected, including 48 rmtB-positive KPC-KP (RPKP) and 36 rmtB-negative KPC-KP (RNKP) isolates. All KPC-KP isolates were multidrug resistant, with colistin and tigecycline being the most active agents. Compared with RNKP, RPKP displayed a much severer resistance phenotype. Susceptibility rates for amikacin (0% for RPKP versus 88.9% for RNKP, p < 0.01), fosfomycin (8.5% for RPKP versus 88.9% for RNKP, p < 0.01), and minocycline (6.7% for RPKP versus 52.8% for RNKP, p < 0.01), were all significantly lower in RPKP strains. Isolates belonging to PFGE pulsetype A and sequence type 11 were predominant in both groups, including 39 (81.3%) RPKP and 22 (61.1%) RNKP isolates. Nevertheless, RNKP showed more complex genetic backgrounds compared with RPKP. Diverse clinical characteristics were found in both cohorts, however, no significant differences were observed between RPKP and RNKP patients. CONCLUSIONS: RPKP strains have spread widely and gradually replaced RNKP in our hospital. They seemed to show much severer resistance phenotypes compared with RNKP and had a bigger dissemination potential. Prudent use of available active agents combined with good control practices is therefore mandatory.


Asunto(s)
Infecciones por Klebsiella/epidemiología , Klebsiella pneumoniae/enzimología , Metiltransferasas/genética , beta-Lactamasas/genética , Adulto , Anciano , Antibacterianos/farmacología , China/epidemiología , Estudios de Cohortes , Electroforesis en Gel de Campo Pulsado , Femenino , Genotipo , Hospitales Universitarios , Humanos , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/clasificación , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/aislamiento & purificación , Masculino , Metiltransferasas/metabolismo , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Tipificación de Secuencias Multilocus , Reacción en Cadena de la Polimerasa , Estudios Retrospectivos , beta-Lactamasas/metabolismo
6.
Adv Healthc Mater ; 7(1)2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28941042

RESUMEN

Despite the tremendous advancements that have been made in biomedical research, Mycobacterium tuberculosis (TB) still remains one of the top 10 causes of death worldwide, outpacing the Human Immunodeficiency Virus as a leading cause of death from an infectious disease. In the light of such significant disease burden, tremendous efforts have been made worldwide to stem this burgeoning spread of disease. The use of nanomaterials in TB management has increased in the past decade, particularly in the areas of early TB detection, prevention, and treatment. Nanomaterials have been proven to be efficacious in the rapid and accurate detection of TB pathogens. Novel nanocarriers have also shown tremendous promise in improving drug delivery, potentially enhancing drug concentrations in target organs while at the same time, reducing treatment frequency. In addition, the engineering of antigen nanocarriers represents an exciting front in TB research, potentially paving the way for the successful development of a new class of effective TB vaccines. This article discusses epidemiology and pathogenesis of TB infections, current TB therapeutics, advanced nanomaterials for anti-TB drug delivery, and TB vaccines. In addition, challenges and future perspectives in developing safe and effective nanomaterials in TB diagnosis and therapy are also presented.


Asunto(s)
Nanoestructuras , Tuberculosis/diagnóstico , Tuberculosis/prevención & control , Animales , Sistemas de Liberación de Medicamentos , Humanos
7.
Infect Dis (Lond) ; 47(10): 673-85, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25915177

RESUMEN

Osteomyelitis caused by nontuberculous mycobacteria (NTM) can have severe consequences and a poor prognosis. Physicians therefore need to be alert to this condition, especially in immunocompromised patients. Although the pathogenesis of NTM osteomyelitis is still unclear, studies in immunodeficient individuals have revealed close relationships between NTM osteomyelitis and defects associated with the interleukin-12-interferon-γ-tumor necrosis factor-α axis, as well as human immunodeficiency virus infection, various immunosuppressive conditions, and diabetes mellitus. Culture and species identification from tissue biopsies or surgical debridement tissue play crucial roles in diagnosing NTM osteomyelitis. Suitable imaging examinations are also important. Adequate surgical debridement and the choice of appropriate, combined antibiotics for long-term anti-mycobacterial chemotherapy, based on in vitro drug susceptibility tests, are the main therapies for these bone infections. Bacillus Calmette-Guerin vaccination might have limited prophylactic value. The use of multiple drugs and long duration of treatment mean that the therapeutic process needs to be monitored closely to detect potential side effects. Adequate duration of anti-mycobacterial chemotherapy together with regular monitoring with blood and imaging tests are key factors determining the recovery outcome in patients with NTM osteomyelitis.


Asunto(s)
Infecciones por Mycobacterium no Tuberculosas/microbiología , Infecciones por Mycobacterium no Tuberculosas/terapia , Micobacterias no Tuberculosas/patogenicidad , Osteomielitis/microbiología , Osteomielitis/terapia , Adulto , Complicaciones de la Diabetes , Diabetes Mellitus , Susceptibilidad a Enfermedades , VIH/patogenicidad , Humanos , Huésped Inmunocomprometido , Interferón gamma/inmunología , Interleucina-12/inmunología , Infecciones por Mycobacterium no Tuberculosas/etiología , Osteomielitis/etiología , Factor de Necrosis Tumoral alfa/inmunología
8.
Int J Pharm Compd ; 10(3): 187-92, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-23974231

RESUMEN

The purpose of this study was to assess whether the satisfaction of women who took part in the pharmacist-administered bioidentical hormone replacement therapy consultation service at an urban compounding pharmacy has improved since implementation of a follow-up call program. A questionnaire was mailed to 200 randomly selected women who completed hormone replacement therapy consultation and received all three follow-up calls from the pharmacy during the period from July 22, 2003, to April 22, 2004. The returned surveys were tabulated and analyzed, and independent t-tests were used to compare data collected in 2001 with that collected in 2004 on questionnaire items of interest. Of the 200 surveys sent out to patients, 125 were returned completed (a response rate of 62.5%). Over 50% of the respondents heard about the hormone replacement therapy program through referral from their healthcare provider, and 34.4% from a friend or a relative. A large majority (95.9%) of the respondents either agreed or strongly agreed that the follow-up calls were helpful; however, only 73.8% felt comfortable discussing their concerns with student interns, who were responsible for making the follow-up calls. Most (95.2) of the respondents reported no new health conditions since initiation of natural hormone replacement therapy. The t-tests revealed improvement in patient satisfaction items between 2001 and 2004, indicating that patient satisfaction with the consultation service improved from 2001 to 2004, and most of the differences were statistically significant (P less than 0.05). The survey results also showed that participants were happy about the follow-up calls, which perhaps contributed to the increase in satisfaction.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA